X

Biotechnology

Viking Therapeutics Inc (NASDAQ: VKTX) Q4 2019 Earnings Call Transcript

Viking Therapeutics Inc  (NASDAQ: VKTX) Q4 2019 Earnings Conference Call February 26, 2020 Corporate Participants: Stephanie C. Diaz -- President and Chief Executive…

Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice…

Companies that are working on the coronavirus vaccine

The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the…

Altimmune (ALT) reports FY19 results; announces vaccine candidate for COVID-19

Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last…

Ocugen (OCGN) posts narrower-than-expected loss in FY19

Ocugen, Inc. (NASDAQ: OCGN) reported a wider loss in fiscal 2019 due to expenses related to the change in fair…

Amarin Corporation plc  (NASDAQ: AMRN) Q4 2019 Earnings Call Transcript

Amarin Corporation plc  (NASDAQ: AMRN) Q4 2019 Earnings Conference Call February 25, 2020 Corporate participants: Elisabeth Schwartz -- Senior Director of Investor…

Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot

-- Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. --…

Hopes high for Mylan’s Upjohn merger even as epidemic mars short-term prospects

Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business…

Why investors need to take note as Veru Inc transforms into a prostate cancer firm

According to the American Cancer Society, prostate cancer is the second most common form of cancer among men in the US,…

Three biotech stocks popped up today on Covid-19 treatment related announcements

Biotech companies all over the world have been trying to find the treatment and vaccine for the coronavirus pandemic since…

Catalyst Pharmaceutical (CPRX): Q4 2019 Earnings Snapshot

-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected. --…

CorMedix (NYSE: CRMD): Q4 2019 Earnings Snapshot

-- CorMedix Inc. (NYSE: CRMD) reported a fourth-quarter 2019 loss of $0.21 per share versus a loss of $0.24 per…

Achieve Life Sciences (ACHV): Q4 2019 Earnings Snapshot

-- Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to…

Fresh hope for Covid-19 patients as AbbVie (ABBV) leads studies on HIV drug

For some of the leading drugmakers, currently, the first priority is to find an effective treatment for Covid-19, which was…

Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot

-- Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the…

Novavax (NVAX) posts wider-than-expected loss in Q4

Novavax Inc. (NASDAQ: NVAX) reported a narrower loss for the fourth quarter of 2019 helped by higher revenue and lower…

Avid Bioservices (CDMO) Q3 2020 Earnings Snapshot

-- Avid Bioservices (NASDAQ: CDMO) reported a loss of $0.## per share for its third quarter of 2020 vs. expected…

Catabasis Pharmaceuticals (NASDAQ: CATB): Q4 2019 Earnings Snapshot

-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) reported a net loss of $6.6 million or $0.55 per share for the fourth…

Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot

-- Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per…

Minerva Neurosciences (NASDAQ: NERV): Q4 2019 Earnings Snapshot

-- Minerva Neurosciences Inc. (NASDAQ: NERV) reported a fourth-quarter 2019 loss of $29.9 million or $0.77 per share, wider than…

BioXcel Therapeutics (BTAI) Q4 loss widens on higher expenses

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported a wider net loss for the fourth quarter, owing to an increase in research…